FII increased stake in this multibagger pharma stock; Company posted record Q3FY24 profits!
Foreign Institutional Investors (FIIs) had progressively increased their ownership in the company to 3.22 per cent
Lincoln Pharmaceuticals Ltd, a key player in India's healthcare sector, posted a net profit of Rs 28.04 crore in Q3 FY24, marking a significant increase of 29.75 per cent compared to the same period last year. Total income for Q3 FY24 stood at Rs 157.47 crore, showing a robust growth of 12.38 per cent year-on-year. The company's earnings before interest, taxes, depreciation, and amortization (EBITDA) also saw a substantial rise, reaching Rs 40.67 crore, up by 22.91 per cent from Q3 FY23.
Here's a simplified breakdown of the financial highlights:
|
Particulars
|
Q3 FY24
|
Q3 FY23
|
Change YoY (per cent)
|
9M FY24
|
9M FY23
|
Change YoY (per cent)
|
|
Total Income
|
157.47
|
140.12
|
12.38
|
465.46
|
416.39
|
11.78
|
|
EBITDA
|
40.67
|
33.09
|
22.91
|
108.93
|
91.1
|
19.57
|
|
Profit before Tax
|
37.71
|
30.52
|
23.56
|
100.02
|
83.47
|
19.83
|
|
Net Profit
|
28.04
|
21.61
|
29.75
|
74.71
|
60.34
|
23.84
|
|
E.P.S (Rs.)
|
14
|
10.79
|
29.75
|
37.3
|
30.12
|
23.84
|
The company's strong performance reflects its focus on innovation and expansion. With a portfolio comprising over 1,700 registered products and 700 more in development, Lincoln Pharma aims to reinforce its presence in lifestyle, chronic, women's healthcare, and dermatology segments, while continuing to strengthen its acute care offerings. In FY23, it introduced 18 new products domestically and submitted over 130 export dossiers. Additionally, the company's commitment to sustainability is evident in its initiatives such as the installation of a solar plant and windmills to reduce energy costs and environmental impact.
By December 2023, Foreign Institutional Investors (FIIs) had progressively increased their ownership in the company to 3.22 per cent, up from 1.44 per cent recorded in December 2022.
About Company
Lincoln Pharmaceuticals Ltd, established in 1979, is a leading healthcare firm in Gujarat, India. With over 600 formulations across 15 therapeutic areas, the company boasts a robust product portfolio and a strong domestic and international presence. Its two manufacturing facilities adhere to stringent quality standards and hold various certifications. Notably, the company prioritizes innovation, evident in its R&D efforts, with numerous patents and government recognition.
Additionally, to enhance its environmental sustainability efforts, the company has installed a new 1 MW solar plant on its factory rooftop, along with two windmills. This initiative has enabled the generation of renewable energy, covering approximately 65 per cent of our energy consumption. Consequently, it has led to substantial cost savings on electricity and facilitated the company's transition towards self-sufficiency and eco-friendly operations.
With over 600 formulations across 15 therapeutic areas, the company boasts a robust product portfolio encompassing anti-infective, respiratory, gynaecology, cardiovascular, CNS, antibacterial, antidiabetic, and antimalarial medications, among others. Moreover, Lincoln Pharma has filed over 25 patent applications and has been granted seven patents, underscoring its commitment to innovation and advancement in pharmaceuticals.
The stock has given a multibagger returns of 108.60 per cent over 1 year and is currently up by 5.15 per cent ytd. Investors should keep an eye on this Smallcap pharma stock!
Disclaimer: The article is for informational purposes only and not investment advice.
For more such updates on the go, Click here to join our WhatsApp Channel